Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.

Oncotarget · 2014 · PMC4170644 · PMID 25010037

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP =0.08so close (0.05 < p ≤ 0.1)

Only for the combination of VX-970 and cisplatin was a relationship observed between response and TP53 status, however this did not reach statistical significance ( P =0.08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.